Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07337577 · ClinicalTrials.gov registry record · NA
Large Language Model-Generated Messages to Improve Guideline-Directed Medical Therapy in Heart Failure
A NA study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 500
- Enrollment target
NCT07337577: Clinical Trial NA study, sponsored by Brigham and Women's Hospital.
NCT07337577 is a NA study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 500 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07337577, a NA study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
Study Summary
This study is an investigator-initiated, cluster-randomized implementation trial evaluating a large language model (LLM)-based clinical decision support (CDS) tool designed to improve guideline-directed medical therapy (GDMT) for adult patients with heart failure seen in outpatient cardiology clinics at Mass General Brigham. For eligible heart failure encounters, the CDS tool reviews existing electronic health record (EHR) data, including diagnoses, medications, vital signs, laboratory results, and recent notes, and generates brief, clinician-facing messages suggesting opportunities to initiate or optimize GDMT and highlighting relevant safety considerations. Messages are delivered to cardiology providers via Epic InBasket and/or institutional email prior to scheduled visits. The tool is advisory only and cannot place orders or change medications automatically; all treatment decisions remain at the discretion of the treating clinician and patient. Cardiology providers are assigned at the provider/clinic level to early implementation of the CDS tool versus usual care (no messages) during the initial phase. The primary outcome is GDMT optimization within 30 days of an index visit. Secondary outcomes include feasibility of CDS generation and delivery and a 30-day safety composite (e.g., heart failure hospitalization, acute kidney injury, hyperkalemia, hypotension or bradyarrhythmia plausibly related to GDMT).
Primary Outcome
Among eligible HF encounters, the proportion with initiation of at least one new GDMT class not previously prescribed and/or uptitration of at least one existing GDMT medication during or within 30 days after the index visit, comparing early-implementation vs usual care arms.
Interventions
- DEVICE LLM-GDMT Clinical Decision Support Tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-12-01 |
| Phase | NA |
What is known before NCT07337577 opens enrollment
NCT07337577 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 1 intervention - of which LLM-GDMT Clinical Decision Support Tool is the first listed.
NCT07337577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07337577 about?
NCT07337577 is a clinical study titled "Large Language Model-Generated Messages to Improve Guideline-Directed Medical Therapy in Heart Failure". This study is an investigator-initiated, cluster-randomized implementation trial evaluating a large language model (LLM)-based clinical decision support (CDS) tool designed to improve guideline-directed medical therapy (GDMT) for adult patients with heart failure seen in outpatient cardiology clinic...
What is the current status of trial NCT07337577?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2026-06-01. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07337577?
The interventions under investigation include: LLM-GDMT Clinical Decision Support Tool (DEVICE).
Who is sponsoring clinical trial NCT07337577?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07337577's enrollment target sits among peer trials
500 193rd of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI